CX3CL1

CX3CL1

CX3CL1 Molekülinformation

Molecule Name
C-X3-C motif chemokine ligand 1
Molekülalias
CX3CL1,Fractalkine
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Small Inducible Cytokine Subfamily D (Cys-X3-Cys), Member 1 (Fractalkine, Neurotactin),Small Inducible Cytokine Subfamily D (Cys-X3-Cys), Member-1,CX3CL1,Small-inducible cytokine D1,FKN,Fractalkine,A-152E5.2,C-X3-C Motif Chemokine Ligand 1,Chemokine (C-X3-C Motif) Ligand 1,CX3C Membrane-Anchored Chemokine,C-X3-C Motif Chemokine 1,Neurotactin,SCYD1,NTT,C3Xkine,ABCD-3,CXC3C,CXC3,NTN,Chemokine CX3CL1
Molekülhintergrund
Fractalkine is also known as C-X3-C motif chemokine 1 (CX3CL1) and neurotactin. Fractalkine is a large cytokine protein of 373 amino acids, it contains multiple domains and is the only known member of the CX3C chemokine family. Fractalkine is found commonly throughout the brain, particularly in neural cells, and its receptor is known to be present on microglial cells. It has also been found to be essential for microglial cell migration. CX3CL1 is also up-regulated in the hippocampus during a brief temporal window following spatial learning, the purpose of which may be to regulate glutamate-mediated neurotransmission tone. This indicates a possible role for the chemokine in the protective plasticity process of synaptic scaling.

CX3CL1 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
QuetmolimabE-6011; KANAB-001Phase 2 ClinicalEisai Co Ltd
Arthritis, Rheumatoid; Cholangitis, Sclerosing; Crohn Disease
Details